Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men

James W. Overstreet, Vivian L. Fuh, John Gould, Stuart S. Howards, Michael M. Lieber, Wayne Hellstrom, Sander Shapiro, Peter Carroll, Randle S. Corfman, Steven Petrou, Ronald W Lewis, Phillip Toth, Tom Shown, Johnny Roy, Jonathan P. Jarow, Jaime Bonilla, Carol A. Jacobsen, Daniel Z. Wang, Keith D. Kaufman

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Purpose: Finasteride, an oral type 2, 5α-reductase inhibitor, is used in 1 mg. daily doses for the treatment of male pattern hair loss. A dose of 5 mg. finasteride daily reduces ejaculate volume by approximately 25%, and reduces prostate volume by approximately 20% and serum prostate specific antigen (PSA) by approximately 50% in men with benign prostatic hyperplasia. To our knowledge no data exist on the effect of 1 mg. finasteride daily on ejaculate volume or other semen parameters, or on the prostate in young men. Therefore, we studied the potential effect and reversibility of effect of 1 mg. finasteride daily on spermatogenesis, semen production, the prostate and serum PSA in young men. Materials and Methods: In this double-blind, placebo controlled multicenter study 181 men 19 to 41 years old were randomized to receive I mg. finasteride or placebo for 48 weeks followed by a 60-week off- drug period. Of the 181 men 79 were included in a subset for the collection and analysis of sequential semen samples. Results: There were no significant effects of I mg. finasteride on sperm concentration, total sperm per ejaculate, sperm motility or morphology. Ejaculate volume in subjects on finasteride decreased 0.3 mL (-11%) compared to a decrease of 0.2 ml. (-8%) for placebo, with a median between treatment group difference of -0.03 ml. (1%, 90% confidence interval -10.4 to 13.1, p = 0.915). There were significant but small decreases in prostate volume (-2.6%) and serum PSA (- 0.2 ng./ml.) in the finasteride group, which reversed on discontinuation of the drug. Conclusions: Treatment with 1 mg. finasteride daily for 48 weeks did not affect spermatogenesis or semen production in young men. The effects of 1 mg. finasteride daily on prostate volume and serum PSA in young men without benign prostatic hyperplasia were small and reversible on discontinuation of the drug.

Original languageEnglish (US)
Pages (from-to)1295-1300
Number of pages6
JournalJournal of Urology
Volume162
Issue number4
DOIs
StatePublished - Jan 1 1999

Fingerprint

Finasteride
Spermatogenesis
Semen
Prostate
Prostate-Specific Antigen
Therapeutics
Placebos
Prostatic Hyperplasia
Serum
Spermatozoa
Pharmaceutical Preparations
Semen Analysis
Sperm Motility
Alopecia
Double-Blind Method
Multicenter Studies
Oxidoreductases
Confidence Intervals

Keywords

  • Finasteride
  • Prostate
  • Semen
  • Testosterone 5-alpha-reductase

ASJC Scopus subject areas

  • Urology

Cite this

Overstreet, J. W., Fuh, V. L., Gould, J., Howards, S. S., Lieber, M. M., Hellstrom, W., ... Kaufman, K. D. (1999). Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. Journal of Urology, 162(4), 1295-1300. https://doi.org/10.1016/S0022-5347(05)68270-5

Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. / Overstreet, James W.; Fuh, Vivian L.; Gould, John; Howards, Stuart S.; Lieber, Michael M.; Hellstrom, Wayne; Shapiro, Sander; Carroll, Peter; Corfman, Randle S.; Petrou, Steven; Lewis, Ronald W; Toth, Phillip; Shown, Tom; Roy, Johnny; Jarow, Jonathan P.; Bonilla, Jaime; Jacobsen, Carol A.; Wang, Daniel Z.; Kaufman, Keith D.

In: Journal of Urology, Vol. 162, No. 4, 01.01.1999, p. 1295-1300.

Research output: Contribution to journalArticle

Overstreet, JW, Fuh, VL, Gould, J, Howards, SS, Lieber, MM, Hellstrom, W, Shapiro, S, Carroll, P, Corfman, RS, Petrou, S, Lewis, RW, Toth, P, Shown, T, Roy, J, Jarow, JP, Bonilla, J, Jacobsen, CA, Wang, DZ & Kaufman, KD 1999, 'Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men', Journal of Urology, vol. 162, no. 4, pp. 1295-1300. https://doi.org/10.1016/S0022-5347(05)68270-5
Overstreet, James W. ; Fuh, Vivian L. ; Gould, John ; Howards, Stuart S. ; Lieber, Michael M. ; Hellstrom, Wayne ; Shapiro, Sander ; Carroll, Peter ; Corfman, Randle S. ; Petrou, Steven ; Lewis, Ronald W ; Toth, Phillip ; Shown, Tom ; Roy, Johnny ; Jarow, Jonathan P. ; Bonilla, Jaime ; Jacobsen, Carol A. ; Wang, Daniel Z. ; Kaufman, Keith D. / Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men. In: Journal of Urology. 1999 ; Vol. 162, No. 4. pp. 1295-1300.
@article{ca17d6b634ba4c6d8d89ac23c1056587,
title = "Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men",
abstract = "Purpose: Finasteride, an oral type 2, 5α-reductase inhibitor, is used in 1 mg. daily doses for the treatment of male pattern hair loss. A dose of 5 mg. finasteride daily reduces ejaculate volume by approximately 25{\%}, and reduces prostate volume by approximately 20{\%} and serum prostate specific antigen (PSA) by approximately 50{\%} in men with benign prostatic hyperplasia. To our knowledge no data exist on the effect of 1 mg. finasteride daily on ejaculate volume or other semen parameters, or on the prostate in young men. Therefore, we studied the potential effect and reversibility of effect of 1 mg. finasteride daily on spermatogenesis, semen production, the prostate and serum PSA in young men. Materials and Methods: In this double-blind, placebo controlled multicenter study 181 men 19 to 41 years old were randomized to receive I mg. finasteride or placebo for 48 weeks followed by a 60-week off- drug period. Of the 181 men 79 were included in a subset for the collection and analysis of sequential semen samples. Results: There were no significant effects of I mg. finasteride on sperm concentration, total sperm per ejaculate, sperm motility or morphology. Ejaculate volume in subjects on finasteride decreased 0.3 mL (-11{\%}) compared to a decrease of 0.2 ml. (-8{\%}) for placebo, with a median between treatment group difference of -0.03 ml. (1{\%}, 90{\%} confidence interval -10.4 to 13.1, p = 0.915). There were significant but small decreases in prostate volume (-2.6{\%}) and serum PSA (- 0.2 ng./ml.) in the finasteride group, which reversed on discontinuation of the drug. Conclusions: Treatment with 1 mg. finasteride daily for 48 weeks did not affect spermatogenesis or semen production in young men. The effects of 1 mg. finasteride daily on prostate volume and serum PSA in young men without benign prostatic hyperplasia were small and reversible on discontinuation of the drug.",
keywords = "Finasteride, Prostate, Semen, Testosterone 5-alpha-reductase",
author = "Overstreet, {James W.} and Fuh, {Vivian L.} and John Gould and Howards, {Stuart S.} and Lieber, {Michael M.} and Wayne Hellstrom and Sander Shapiro and Peter Carroll and Corfman, {Randle S.} and Steven Petrou and Lewis, {Ronald W} and Phillip Toth and Tom Shown and Johnny Roy and Jarow, {Jonathan P.} and Jaime Bonilla and Jacobsen, {Carol A.} and Wang, {Daniel Z.} and Kaufman, {Keith D.}",
year = "1999",
month = "1",
day = "1",
doi = "10.1016/S0022-5347(05)68270-5",
language = "English (US)",
volume = "162",
pages = "1295--1300",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Chronic treatment with finasteride daily does not affect spermatogenesis or semen production in young men

AU - Overstreet, James W.

AU - Fuh, Vivian L.

AU - Gould, John

AU - Howards, Stuart S.

AU - Lieber, Michael M.

AU - Hellstrom, Wayne

AU - Shapiro, Sander

AU - Carroll, Peter

AU - Corfman, Randle S.

AU - Petrou, Steven

AU - Lewis, Ronald W

AU - Toth, Phillip

AU - Shown, Tom

AU - Roy, Johnny

AU - Jarow, Jonathan P.

AU - Bonilla, Jaime

AU - Jacobsen, Carol A.

AU - Wang, Daniel Z.

AU - Kaufman, Keith D.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Purpose: Finasteride, an oral type 2, 5α-reductase inhibitor, is used in 1 mg. daily doses for the treatment of male pattern hair loss. A dose of 5 mg. finasteride daily reduces ejaculate volume by approximately 25%, and reduces prostate volume by approximately 20% and serum prostate specific antigen (PSA) by approximately 50% in men with benign prostatic hyperplasia. To our knowledge no data exist on the effect of 1 mg. finasteride daily on ejaculate volume or other semen parameters, or on the prostate in young men. Therefore, we studied the potential effect and reversibility of effect of 1 mg. finasteride daily on spermatogenesis, semen production, the prostate and serum PSA in young men. Materials and Methods: In this double-blind, placebo controlled multicenter study 181 men 19 to 41 years old were randomized to receive I mg. finasteride or placebo for 48 weeks followed by a 60-week off- drug period. Of the 181 men 79 were included in a subset for the collection and analysis of sequential semen samples. Results: There were no significant effects of I mg. finasteride on sperm concentration, total sperm per ejaculate, sperm motility or morphology. Ejaculate volume in subjects on finasteride decreased 0.3 mL (-11%) compared to a decrease of 0.2 ml. (-8%) for placebo, with a median between treatment group difference of -0.03 ml. (1%, 90% confidence interval -10.4 to 13.1, p = 0.915). There were significant but small decreases in prostate volume (-2.6%) and serum PSA (- 0.2 ng./ml.) in the finasteride group, which reversed on discontinuation of the drug. Conclusions: Treatment with 1 mg. finasteride daily for 48 weeks did not affect spermatogenesis or semen production in young men. The effects of 1 mg. finasteride daily on prostate volume and serum PSA in young men without benign prostatic hyperplasia were small and reversible on discontinuation of the drug.

AB - Purpose: Finasteride, an oral type 2, 5α-reductase inhibitor, is used in 1 mg. daily doses for the treatment of male pattern hair loss. A dose of 5 mg. finasteride daily reduces ejaculate volume by approximately 25%, and reduces prostate volume by approximately 20% and serum prostate specific antigen (PSA) by approximately 50% in men with benign prostatic hyperplasia. To our knowledge no data exist on the effect of 1 mg. finasteride daily on ejaculate volume or other semen parameters, or on the prostate in young men. Therefore, we studied the potential effect and reversibility of effect of 1 mg. finasteride daily on spermatogenesis, semen production, the prostate and serum PSA in young men. Materials and Methods: In this double-blind, placebo controlled multicenter study 181 men 19 to 41 years old were randomized to receive I mg. finasteride or placebo for 48 weeks followed by a 60-week off- drug period. Of the 181 men 79 were included in a subset for the collection and analysis of sequential semen samples. Results: There were no significant effects of I mg. finasteride on sperm concentration, total sperm per ejaculate, sperm motility or morphology. Ejaculate volume in subjects on finasteride decreased 0.3 mL (-11%) compared to a decrease of 0.2 ml. (-8%) for placebo, with a median between treatment group difference of -0.03 ml. (1%, 90% confidence interval -10.4 to 13.1, p = 0.915). There were significant but small decreases in prostate volume (-2.6%) and serum PSA (- 0.2 ng./ml.) in the finasteride group, which reversed on discontinuation of the drug. Conclusions: Treatment with 1 mg. finasteride daily for 48 weeks did not affect spermatogenesis or semen production in young men. The effects of 1 mg. finasteride daily on prostate volume and serum PSA in young men without benign prostatic hyperplasia were small and reversible on discontinuation of the drug.

KW - Finasteride

KW - Prostate

KW - Semen

KW - Testosterone 5-alpha-reductase

UR - http://www.scopus.com/inward/record.url?scp=0032843781&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032843781&partnerID=8YFLogxK

U2 - 10.1016/S0022-5347(05)68270-5

DO - 10.1016/S0022-5347(05)68270-5

M3 - Article

C2 - 10492183

AN - SCOPUS:0032843781

VL - 162

SP - 1295

EP - 1300

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -